Background: Targeted therapy is used to treat patients with a BRAF-mutated metastatic melanoma and is continued until disease progression or severe toxicity. No robust data on the management of patients achieving a complete remission (CR) are available.
Main Objective: To determine the relapse rate in the first year after targeted therapy discontinuation in patients in CR.
J Allergy Clin Immunol Pract
January 2022